Skip to main content

European Union Safe Harbor Policy

BayBiotech.NET

The European Commission’s Directive on Data Protection w.e.f.October of 1998 prohibits the transfer of personal data to non-European Union nations that do not meet the European “adequacy” standard for privacy protection of the personal data. For purposes of the policy, "personal information" means information that:

 is transferred from the European Union to the United States;
 is recorded in any form;
 is about, or pertains to, a specific individual or can be linked to that individual.
While both the United States and the European Union share the goal of enhancing privacy protection for their citizens, the United States takes a different approach to privacy from that taken by the European Union.
With a goal to bridge the different privacy approaches between the United States and European Union and provide a streamlined means for U.S. organizations to comply with the Directive, the U.S. Department of Commerce in consultation with the European Commission developed a "Safe Harbor" framework to provide the information an organization should need to evaluate – and then join – the Safe Harbor.
Safe Harbor Directive applies to all personal information that is handled by an organization, including on-line, off-line, and manually processed data.

Where the company receives personal information from its subsidiaries, affiliates, or other entities in the EU, the company will use and disclose such information in accordance with the purposes for which it was originally collected, or in accordance with the notices provided by such entities.
The company will provide notice and provide individuals with an opportunity to "opt out" if such personal information is to be disclosed to a third party or used for a purpose incompatible with the purpose for which it was originally collected.
For sensitive information, affirmative or explicit, the company will provide notice and individual choice will be given to "opt-in" if such sensitive information is to be disclosed to a third party or used for a purpose other than the purpose for which it was originally collected. In order to disclose such information, one must have individual’s permission to make the disclosure required by law or professional standards providing adequate level of privacy protection and is reasonably related to the sale or other disposition of the business.

For data security purposes, the organization must employ various physical, electronic, and managerial measures, designed to provide personal information with reasonable protection from accidental loss or destruction, improper use, alteration, or disclosure.

The EU’s Data Protection Directive, implemented in 1998, provides member states with the authority to block such transfers to countries whose privacy enforcement regime does not meet the directive’s requirements. Under the US-EU Safe Harbor Framework, the United States received an “adequacy” determination from the European Commission limited to those U.S. organizations that self-certified to Safe Harbor which allows data transfers to take place without prior approval.
To find out more about the Safe Harbor Framework and the qualification Checklist follow the link:
http://www.export.gov/safeharbor/

Comments

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...

Food Safety Bill: A major overhaul of the Food Safety System

BayBiotech.NET The recently passed Food Safety bill is being considered to be a major overhaul of the food safety system in the United States and is considered to change the mission of the FDA, focusing it on preventing food-borne illnesses rather than reacting after an outbreak occurs. Under this legislation, food manufacturers are required to examine their processing systems to identify possible ways that food products can become contaminated and to develop detailed plans to keep that from happening. Companies must share those plans with the F.D.A., and provide the agency with records, including product test results, showing how effectively they carry them out. To read more about it follow the link